Gustavo Rojas-Velasco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gustavo Rojas-Velasco has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Manzur-Sandoval
Cardiovascular Critical Care Unit Instituto Nacional de Cardiología Ignacio Chávez Mexico City Mexico
4 shared publications - Edgar García-Cruz
Instituto Nacional de Cardiología Ignacio Chávez
2 shared publications - Rodrigo Gopar-Nieto
Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico
2 shared publications - Adriana Torres-Machorro
Division of Vascular and Endovascular Surgery, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico
1 shared publication Adrián Eduardo Carrillo Rodríguez
Secretaría de Salud (Ssa). Instituto Nacional de Cardiología "Ignacio Chávez". Unidad de Investigación Clínica de Terapia Intensiva Postquirúrgica. Ciudad de México. México
1 shared publication- Aldo Pérez-Manjarrez
Terapia Intensiva cardiovascular, Instituto Nacional de Cardiología «Ignacio Chávez», Ciudad de México, México
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 41 (1)
Utility of the Charlson Comorbidity Index in the Preoperative Evaluation of Patients Undergoing Cardiac Surgery
The Charlson Comorbidity Index (CCI) is used for assessing comorbidities and estimating risk of adverse outcomes in surgical patients. In cardiac surgery, the burden of comorbidities can significantly influence incidence of postoperative complications and mortality. This study evaluates the utility of CCI in predicting perioperative complications in patients undergoing cardiac surgery. Observational cross-sectional study with retrospective data including 483 adult patients who underwent cardiac surgery with cardiopulmonary bypass at the Instituto Nacional de Cardiología Ignacio Chávez from June 2022 to December 2023. Patients were grouped by preoperative CCI: mild (0 - 1), moderate (2), and severe (≥ 3). Statistical analyses (chi-square, Mann-Whitney U, logistic regression) assessed the association between CCI and postoperative complications, adjusting for age and sex. Patients with severe comorbidity had higher rates of postoperative complications, including delirium (27.3% vs. 9.4%, P = 0.00), stroke (P = 0.03), transfusion (69.7% vs. 47.2%, P = 0.04), and renal replacement therapy (18.2% vs. 5.3%, P = 0.02). Median Sequential Organ Failure Assessment scores at 24 hours were significantly higher (P = 0.00). Logistic regression adjusted for age, sex, and coronary artery bypass grafting identified delirium (odds ratio [OR]: 3.13), nosocomial pneumonia (OR: 3.10), acute kidney injury (OR: 2.28), and renal replacement therapy (OR: 4.10) as independent predictors of severe comorbidity. The CCI is a valuable tool for predicting postoperative complications in patients undergoing cardiac surgery. Early identification of comorbidities is essential for perioperative planning and optimizing clinical outcomes. Integrating the CCI into routine clinical practice is recommended to enhance patient management.
- 1 January 2026
- Published by Sociedade Brasileira de Cirurgia Cardiovascular in Brazilian Journal of Cardiovascular Surgery
- Vol. 41 (1)
Open AccessUtility of the Charlson Comorbidity Index in the Preoperative Evaluation of Patients Undergoing Cardiac Surgery
The Charlson Comorbidity Index (CCI) is used for assessing comorbidities and estimating risk of adverse outcomes in surgical patients. In cardiac surgery, the burden of comorbidities can significantly influence incidence of postoperative complications and mortality. This study evaluates the utility of CCI in predicting perioperative complications in patients undergoing cardiac surgery. Observational cross-sectional study with retrospective data including 483 adult patients who underwent cardiac surgery with cardiopulmonary bypass at the Instituto Nacional de Cardiología Ignacio Chávez from June 2022 to December 2023. Patients were grouped by preoperative CCI: mild (0 - 1), moderate (2), and severe (≥ 3). Statistical analyses (chi-square, Mann-Whitney U, logistic regression) assessed the association between CCI and postoperative complications, adjusting for age and sex. Patients with severe comorbidity had higher rates of postoperative complications, including delirium (27.3% vs. 9.4%, P = 0.00), stroke (P = 0.03), transfusion (69.7% vs. 47.2%, P = 0.04), and renal replacement therapy (18.2% vs. 5.3%, P = 0.02). Median Sequential Organ Failure Assessment scores at 24 hours were significantly higher (P = 0.00). Logistic regression adjusted for age, sex, and coronary artery bypass grafting identified delirium (odds ratio [OR]: 3.13), nosocomial pneumonia (OR: 3.10), acute kidney injury (OR: 2.28), and renal replacement therapy (OR: 4.10) as independent predictors of severe comorbidity. The CCI is a valuable tool for predicting postoperative complications in patients undergoing cardiac surgery. Early identification of comorbidities is essential for perioperative planning and optimizing clinical outcomes. Integrating the CCI into routine clinical practice is recommended to enhance patient management.
- Open Access
- 2 May 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 24 (3) , 665-672
ELANE rs17223045C/T and rs3761007G/A variants: Protective factors against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for causing coronavirus disease 2019 (COVID-19). The development and severity of this infectious disease is influenced by a combination of environmental and genetic factors. Angiotensin-converting enzyme 2 (ACE2) facilitates SARS-CoV-2 entry into human cells, with transmembrane serine protease 2 (TMPRSS2) playing a crucial role in S protein priming. Other proteases, such as cathepsin L and elastase, neutrophil-expressed (ELANE), have the capability to prime the S protein and contribute to SARS-CoV-2 infection. ELANE variants have not been previously examined in COVID-19 patients. We aimed to assess the association of single nucleotide variants (SNVs) within ELANE with COVID-19 and biochemical markers. The study included 319 SARS-CoV-2-infected patients and 288 controls. Genotyping of ELANE rs17216663C/T (Pro257Leu), rs17223045C/T (As1n30Asn), and rs3761007G/A was conducted using a 5'-nuclease allelic discrimination assay (TaqMan assay). Our findings indicate that ELANE rs17223045C/T (C vs T: odds ratio [OR] 0.08, P = 0.005, and CC vs CT: OR 0.08, P = 0.005) and rs3761007G/A (G vs A: OR 0.38, P = 0.009, and GG vs GA: OR 0.40, P = 0.008) confer protection against COVID-19. However, these variants were not associated with biochemical markers. In conclusion, our data suggests that ELANE rs17223045C/T and rs3761007G/A SNVs may play a protective role against COVID-19.
- 2 May 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 24 (3) , 665-672
Open AccessELANE rs17223045C/T and rs3761007G/A variants: Protective factors against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for causing coronavirus disease 2019 (COVID-19). The development and severity of this infectious disease is influenced by a combination of environmental and genetic factors. Angiotensin-converting enzyme 2 (ACE2) facilitates SARS-CoV-2 entry into human cells, with transmembrane serine protease 2 (TMPRSS2) playing a crucial role in S protein priming. Other proteases, such as cathepsin L and elastase, neutrophil-expressed (ELANE), have the capability to prime the S protein and contribute to SARS-CoV-2 infection. ELANE variants have not been previously examined in COVID-19 patients. We aimed to assess the association of single nucleotide variants (SNVs) within ELANE with COVID-19 and biochemical markers. The study included 319 SARS-CoV-2-infected patients and 288 controls. Genotyping of ELANE rs17216663C/T (Pro257Leu), rs17223045C/T (As1n30Asn), and rs3761007G/A was conducted using a 5'-nuclease allelic discrimination assay (TaqMan assay). Our findings indicate that ELANE rs17223045C/T (C vs T: odds ratio [OR] 0.08, P = 0.005, and CC vs CT: OR 0.08, P = 0.005) and rs3761007G/A (G vs A: OR 0.38, P = 0.009, and GG vs GA: OR 0.40, P = 0.008) confer protection against COVID-19. However, these variants were not associated with biochemical markers. In conclusion, our data suggests that ELANE rs17223045C/T and rs3761007G/A SNVs may play a protective role against COVID-19.
- Open Access
- 30 September 2023
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 4 (3) , 114-117
El síndrome de norte-sur, una complicación de la asistencia circulatoria con ECMO Venoarterial. Reporte de caso
Presentamos el caso de un paciente masculino de 34 años con diagnóstico previo de síndrome de Marfan que ingresó por Insuficiencia aórtica aguda secundario a dilatación aneurismática de la aorta torácica ascendente. En el posoperatorio se documentó choque cardiogénico poscardiotomía por lo que se inició soporte circulatorio con ECMO venoarterial periférico, el cual desarrolló hipoxemia por neumonía bacteriana y datos compatibles con síndrome norte-sur. Presentamos una revisión, estrategias de canulación no convencional y una alternativa diagnóstica para esta entidad.
- 30 September 2023
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 4 (3) , 114-117
Open AccessEl síndrome de norte-sur, una complicación de la asistencia circulatoria con ECMO Venoarterial. Reporte de caso
Presentamos el caso de un paciente masculino de 34 años con diagnóstico previo de síndrome de Marfan que ingresó por Insuficiencia aórtica aguda secundario a dilatación aneurismática de la aorta torácica ascendente. En el posoperatorio se documentó choque cardiogénico poscardiotomía por lo que se inició soporte circulatorio con ECMO venoarterial periférico, el cual desarrolló hipoxemia por neumonía bacteriana y datos compatibles con síndrome norte-sur. Presentamos una revisión, estrategias de canulación no convencional y una alternativa diagnóstica para esta entidad.
- Open Access
- 1 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 7 (8) , ytad393
Left atrial veno-arterial extracorporeal membrane oxygenation in post-myocardial infarction ventricular septal defect with cardiogenic shock: a case report
Background: Ventricular septal defect (VSD) complicating acute myocardial infarction (MI) represents a life-threatening condition and has a mortality of >90% if left untreated. Case summary: A 53-year-old man with a prior medical history of diabetes and hypertension presented with cardiogenic shock secondary to VSD as a mechanical complication of non-reperfused inferior MI. Discussion: The choice of mechanical support can be difficult in this type of patient. Given the risk of an increased shunt because of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and the increase in left ventricle (LV) afterload, several measures were taken to plan the best ECMO configuration. Given the absence of any real improvement in the LV and an elevated residual ratio between pulmonary and systemic flow (Qp/Qs), the final decision was to switch to left atrial VA-ECMO (LAVA-ECMO). The use of LAVA-ECMO improved the patient’s haemodynamics and allowed his condition to stabilize; LAVA-ECMO is feasible and may be effective as a mechanical circulatory support (MCS) strategy for patients in cardiogenic shock due to VSD as a mechanical complication of acute MI.
- 1 August 2023
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 7 (8) , ytad393
Open AccessLeft atrial veno-arterial extracorporeal membrane oxygenation in post-myocardial infarction ventricular septal defect with cardiogenic shock: a case report
Background: Ventricular septal defect (VSD) complicating acute myocardial infarction (MI) represents a life-threatening condition and has a mortality of >90% if left untreated. Case summary: A 53-year-old man with a prior medical history of diabetes and hypertension presented with cardiogenic shock secondary to VSD as a mechanical complication of non-reperfused inferior MI. Discussion: The choice of mechanical support can be difficult in this type of patient. Given the risk of an increased shunt because of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and the increase in left ventricle (LV) afterload, several measures were taken to plan the best ECMO configuration. Given the absence of any real improvement in the LV and an elevated residual ratio between pulmonary and systemic flow (Qp/Qs), the final decision was to switch to left atrial VA-ECMO (LAVA-ECMO). The use of LAVA-ECMO improved the patient’s haemodynamics and allowed his condition to stabilize; LAVA-ECMO is feasible and may be effective as a mechanical circulatory support (MCS) strategy for patients in cardiogenic shock due to VSD as a mechanical complication of acute MI.
- Open Access
- 3 April 2023
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 157 (3) , 261-266
Use of pulmonary ultrasound to predict in-hospital mortality in patients with COVID-19 infection
- 3 April 2023
- Published by Instituto Mexicano del Seguro Social in Gaceta Médica de México
- Vol. 157 (3) , 261-266
Open AccessUse of pulmonary ultrasound to predict in-hospital mortality in patients with COVID-19 infection
- 2 September 2022
- Published by Bentham Science Publishers Ltd.
- p. 145-206
COVID-19 Pathophysiology, Clinical Manifestations, and Drug Treatment
COVID-19 is caused by a single-stranded RNA encapsulated betacoronavirus, known as SARS-CoV-2, implicated in the pandemic that started in China in 2019. Viral replication consists of five stages that culminate in the release of the new virion. The exaggerated inflammatory response of COVID-19 is characterized by an elevation of acute phase reactants such as C-reactive protein and ferritin. It is associated with an unfavorable clinical course, intensified by abnormal activation of the protein complex called the inflammasome. When the immune response does not control the virus, lung tissue damage occurs that leads to the massive release of proinflammatory cytokines, producing acute respiratory failure syndrome. Vascular permeability is increased; interaction with coagulation factors develops disseminated intravascular coagulation and multiorgan failure. Up to 33% of cases can be asymptomatic. Clinical manifestations can be mild or severe and involve various organs and systems. Among the most commonly affected are: respiratory, cardiovascular, renal, and hematological and coagulation systems. Among the most representative laboratory data are: elevation of inflammatory markers (CRP, inflammatory cytokines, tumor necrosis factor), high levels of D-Dimer, elevation of troponin I, lymphopenia, thrombocytopenia, alteration of liver enzymes and kidney function. There are risk factors and comorbidities that contribute to the severity of the clinical picture (mainly cardiovascular and metabolic diseases): diabetes mellitus, high blood pressure, obesity, chronic lung diseases, cancer, and chronic kidney failure. There are also other genetic factors associated with the host’s immunopathogenesis and response to SARS COV-2 infection. There are various imaging methods that allow adequate identification and involvement of the pulmonary and cardiovascular systems with great sensitivity and specificity (computed tomography and echocardiography). The pandemic imposed decisions with very little information regarding what may be useful as a therapeutic strategy. This uncertainty applies to the treatment indicated in the prevention phase, as well as to the different stages of severity of the disease. In many cases, treatments were applied without having gone through a trial phase but only with the theoretical support of its probable benefit. However, over time, controlled studies showed that they did not provide any benefit and that they could even have a deleterious effect. Other therapies still in use have shown contradictory results in the different clinical trials where they were tested. Very few therapeutic options have shown undisputable benefit so far. The only ones that can modify the presentation or course of the disease are vaccines, which have also been developed in record time and in controlled trials, and all those that have been approved showed a decrease in the risk of infection and in the risk of presenting a severe manifestation of the disease.
- 2 September 2022
- Published by Bentham Science Publishers Ltd.
- p. 145-206
COVID-19 Pathophysiology, Clinical Manifestations, and Drug Treatment
COVID-19 is caused by a single-stranded RNA encapsulated betacoronavirus, known as SARS-CoV-2, implicated in the pandemic that started in China in 2019. Viral replication consists of five stages that culminate in the release of the new virion. The exaggerated inflammatory response of COVID-19 is characterized by an elevation of acute phase reactants such as C-reactive protein and ferritin. It is associated with an unfavorable clinical course, intensified by abnormal activation of the protein complex called the inflammasome. When the immune response does not control the virus, lung tissue damage occurs that leads to the massive release of proinflammatory cytokines, producing acute respiratory failure syndrome. Vascular permeability is increased; interaction with coagulation factors develops disseminated intravascular coagulation and multiorgan failure. Up to 33% of cases can be asymptomatic. Clinical manifestations can be mild or severe and involve various organs and systems. Among the most commonly affected are: respiratory, cardiovascular, renal, and hematological and coagulation systems. Among the most representative laboratory data are: elevation of inflammatory markers (CRP, inflammatory cytokines, tumor necrosis factor), high levels of D-Dimer, elevation of troponin I, lymphopenia, thrombocytopenia, alteration of liver enzymes and kidney function. There are risk factors and comorbidities that contribute to the severity of the clinical picture (mainly cardiovascular and metabolic diseases): diabetes mellitus, high blood pressure, obesity, chronic lung diseases, cancer, and chronic kidney failure. There are also other genetic factors associated with the host’s immunopathogenesis and response to SARS COV-2 infection. There are various imaging methods that allow adequate identification and involvement of the pulmonary and cardiovascular systems with great sensitivity and specificity (computed tomography and echocardiography). The pandemic imposed decisions with very little information regarding what may be useful as a therapeutic strategy. This uncertainty applies to the treatment indicated in the prevention phase, as well as to the different stages of severity of the disease. In many cases, treatments were applied without having gone through a trial phase but only with the theoretical support of its probable benefit. However, over time, controlled studies showed that they did not provide any benefit and that they could even have a deleterious effect. Other therapies still in use have shown contradictory results in the different clinical trials where they were tested. Very few therapeutic options have shown undisputable benefit so far. The only ones that can modify the presentation or course of the disease are vaccines, which have also been developed in record time and in controlled trials, and all those that have been approved showed a decrease in the risk of infection and in the risk of presenting a severe manifestation of the disease.
- Open Access
- 1 December 2020
- Published by Elsevier in Thrombosis Research
- Vol. 196, 268-271
Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
- 1 December 2020
- Published by Elsevier in Thrombosis Research
- Vol. 196, 268-271
Open AccessAsymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
- 10 March 2020
- Published by Universidad Nacional Autonoma de Mexico in Revista de la Facultad de Medicina
- Vol. 63 (2) , 36-45
Ultrasonido pulmonar en Medicina, su utilidad en la práctica clínica
Lung ultrasound has become increasingly important in the evaluation of the thorax and its pathologies. It has proved to be very useful in the evaluation of hospitalized patients, allowing doctors to evaluate and make quick decisions, as well as providing guidance for diagnostic and therapeutic procedures. Ultrasound has many advantages over other studies since it can avoid transferring patients, and it is harmless, accessible and fast. In this article we will review basic concepts of lung ultrasound and its use in the diagnosis of pathologies. Key words: Pulmonary ultrasound; pleura; pneumothorax; pleural effusion.
- 10 March 2020
- Published by Universidad Nacional Autonoma de Mexico in Revista de la Facultad de Medicina
- Vol. 63 (2) , 36-45
Ultrasonido pulmonar en Medicina, su utilidad en la práctica clínica
Lung ultrasound has become increasingly important in the evaluation of the thorax and its pathologies. It has proved to be very useful in the evaluation of hospitalized patients, allowing doctors to evaluate and make quick decisions, as well as providing guidance for diagnostic and therapeutic procedures. Ultrasound has many advantages over other studies since it can avoid transferring patients, and it is harmless, accessible and fast. In this article we will review basic concepts of lung ultrasound and its use in the diagnosis of pathologies. Key words: Pulmonary ultrasound; pleura; pneumothorax; pleural effusion.